CDK4 and breast cancer: The results of our study suggest that combination therapies with gedatolisib and CDK4/6 inhibitors, with or without fulvestrant, could be beneficial both in treatment-naïve BC patients and in patients who progressed after treatment with CDK4/6 inhibitors.